{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:21:13Z","timestamp":1785532873443,"version":"3.56.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rapid progression of Alzheimer\u2019s disease (AD) is primarily caused by compromised neurotrophin functions and decreased tropomyosin receptor kinase expression in the basal forebrain area. The two main pathogenic features of AD are cholinergic-dependent cognitive dysfunctions and amyloidogenic-induced neurodegeneration. Concurrent stimulation of major neurotrophin signalling pathways, such as tropomyosin receptor kinases receptor A and B (TrkA and TrkB), may reduce amyloid-\u03b2-mediated neurotoxicity and cholinergic denervation in the basal forebrain, improving cognitive performance and re-establishing neuronal communication. The development of new medications with dual agonist action towards TrkA and B receptors holds enormous therapeutic potential for managing the symptoms of neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to develop novel dual TrkA\/TrkB receptor agonists for the treatment of AD by enhancing neurotrophin signalling, reducing cholinergic denervation, and mitigating amyloid-\u03b2-induced neurotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An\n                      <jats:italic>in silico<\/jats:italic>\n                      drug discovery pipeline was employed, involving homology and pharmacophore modelling of amitriptyline, virtual screening of ChEMBL compounds, molecular docking, ADMET, MM\/GBSA analysis, DFT calculations and molecular dynamics (MD) simulations for 100 and 300 ns to assess ligand stability and binding behaviour of the ligand\u2013protein complexes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six novel optimised quinoline analogues (OP-1 to OP-6) were identified as computationally predicted dual TrkA\/TrkB agonists by molecular docking (\u22128.90 to \u22125.07 kcal\/mol), MM\/GBSA (\u221240.47 to \u221230.71 kcal\/mol), ADMET and DFT analysis. Furthermore, OP-1, OP-2, and OP-3 exhibit stable binding interactions over 300 ns of MD simulations. The optimised compounds demonstrated favorable computational binding profiles, predicted pharmacokinetic properties, and stable receptor\u2013ligand interactions, identifying them as promising candidates for further experimental validation as potential dual TrkA\/TrkB modulators in Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2026.1779769","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:31:36Z","timestamp":1780291896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated computational-based design of putative dual TrkA\/TrkB agonists for Alzheimer\u2019s disease: pharmacophore modelling, docking, MM\/GBSA, DFT and dynamics studies"],"prefix":"10.3389","volume":"6","author":[{"given":"A.","family":"Vignesh Pandi","sequence":"first","affiliation":[{"name":"Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Malakar","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyaram Bharathi","family":"Jeyabalan","sequence":"additional","affiliation":[{"name":"Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Sanjai","sequence":"additional","affiliation":[{"name":"Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Shevate","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalirajan","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Prashantha Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Mysuru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Justin","sequence":"additional","affiliation":[{"name":"Centre for Neuropharmacology and Experimental Neuroscience, Department of Pharmacology, JSS Academy of Higher Education and Research, JSS College of Pharmacy","place":["Ooty, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.1093\/emboj\/17.24.7282","article-title":"A function-structure model for NGF-activated TRK","volume":"17","author":"Cunningham","year":"1998","journal-title":"EMBO J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibs.2024.02.001","article-title":"TrkB transmembrane domain: bridging structural understanding with therapeutic strategy","volume":"49","author":"Enkavi","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"B6","volume-title":"HOMO-LUMO Energy Gap","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1021\/acs.jmedchem.4c02365","article-title":"Differential neurotoxicity of tricyclic antidepressants and novel derivatives in vitro in a dorsal root ganglion cell culture model","volume":"24","author":"Haller","year":"2007","journal-title":"Eur. J. Anaesthesiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nn1242","article-title":"Dynein motors transport activated Trks to promote survival of target-dependent neurons","volume":"7","author":"Heerssen","year":"2004","journal-title":"Nat. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.chembiol.2009.05.010","article-title":"Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity","volume":"16","author":"Jang","year":"2009","journal-title":"Chem. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s10072-023-06684-1","article-title":"Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson\u2019s","volume":"44","author":"Jeyaram Bharathi","year":"2023","journal-title":"Neurol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-016-0119-y","article-title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer\u2019s disease","volume":"11","author":"Kazim","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.3390\/ijms25105358","article-title":"Leveraging the fragment molecular orbital and MM-GBSA methods in virtual screening for the discovery of novel non-covalent inhibitors targeting the TEAD lipid binding pocket","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1098\/rstb.1996.0030","article-title":"Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview","volume":"351","author":"Lindsay","year":"1996","journal-title":"Philos. Trans. R. Soc. Lond B Biol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11064-025-04509-5","article-title":"Targeting IDO1 in Huntington's Disease: network pharmacology and preclinical evidence from Coffea arabica","volume":"50","author":"Malakar","year":"2025","journal-title":"Neurochem. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111507","DOI":"10.1016\/j.compbiomed.2026.111507","article-title":"Network pharmacology and computational-based approaches to activate NRF2 pathway via KEAP1 and GSK-3\u03b2 inhibition: exploring the possible molecular insights of mangiferin for Alzheimer's","volume":"204","author":"Malakar","year":"2026","journal-title":"Comput. Biol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/bs.ircmb.2014.10.002","article-title":"Biogenesis and function of the NGF\/TrkA signaling endosome","volume":"314","author":"Marlin","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fchem.2023.1205724","article-title":"Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies","volume":"11","author":"Mukhtar","year":"2023","journal-title":"Front. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13019","DOI":"10.1074\/jbc.272.20.13019","article-title":"TrkB variants with deletions in the leucine-rich motifs of the extracellular domain","volume":"272","author":"Ninkina","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B20","unstructured":"Understanding HOMO and LUMO | theory, energy levels and more\n          \n          \n          2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1523\/JNEUROSCI.4736-08.2009","article-title":"Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer\u2019s disease","volume":"29","author":"Peng","year":"2009","journal-title":"J. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1568007023339490","article-title":"Small molecule Trk receptor agonists and other neurotrophic factor mimetics","volume":"1","author":"Pollack","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"16937","DOI":"10.1074\/jbc.M113.463711","article-title":"\u03b2-Amyloid (A\u03b2) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1","volume":"288","author":"Poon","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B24","unstructured":"3D view: 2IFG\n          \n          \n          2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.bbadis.2013.06.012","article-title":"Amyloid beta-induced glycogen synthase kinase 3\u03b2 phosphorylated VDAC1 in Alzheimer\u2019s disease: implications for synaptic dysfunction and neuronal damage","volume":"1832","author":"Reddy","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1098\/rstb.2006.1894","article-title":"Neurotrophin-regulated signalling pathways","volume":"361","author":"Reichardt","year":"2006","journal-title":"Philosophical Trans. R. Soc. B Biol. Sci."},{"key":"B27","unstructured":"Homology modeling with the Schr\u00f6dinger Biologics Suite - Schr\u00f6dinger\n          \n          \n            \n              Rojas\n              A.\n            \n          \n          \n          2025"},{"key":"B28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1673-5374.205084","article-title":"Neurotrophic factors in Alzheimer\u2019s and Parkinson\u2019s diseases: implications for pathogenesis and therapy","volume":"12","author":"Sampaio","year":"2017","journal-title":"Neural Regen. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"26820","DOI":"10.1039\/d1ra03891e","article-title":"Ligand-based pharmacophore modeling and molecular dynamic simulation approaches to identify putative MMP-9 inhibitors","volume":"11","author":"Sanapalli","year":"2021","journal-title":"RSC Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/cells10040721","article-title":"GSK-3 and tau: a key duet in Alzheimer\u2019s disease","volume":"10","author":"Sayas","year":"2021","journal-title":"Cells"},{"key":"B31","volume-title":"Docking and Scoring","year":"2025"},{"key":"B32","volume-title":"Phase","year":""},{"key":"B33","volume-title":"Qikprop","year":""},{"key":"B34","volume-title":"Jaguar for Life Science","year":""},{"key":"B35","volume-title":"Desmond for Life Science","year":""},{"key":"B36","volume-title":"Ligand Designer","year":""},{"key":"B37","unstructured":"How are Prime MM-GBSA calculations carried out, and what solvation model is used? Is this described somewhere in the literature?"},{"key":"B38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/187152708783885174","article-title":"The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors","volume":"7","author":"Skaper","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.2174\/138161211797415995","article-title":"Peptide mimetics of neurotrophins and their receptors","volume":"17","author":"Skaper","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/mcne.1998.0714","article-title":"Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration","volume":"12","author":"Skaper","year":"1998","journal-title":"Mol. Cell Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1017\/S0265021507000154","article-title":"Small-molecule trk agonists: where do we Go from here?","volume":"68","author":"Thompson","year":"2025","journal-title":"J. Med. Chem."},{"key":"B42","volume-title":"ProTox-3.0 - Prediction of Toxicity of Chemicals","year":"2025"},{"key":"B43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/biom10020216","article-title":"hNGF peptides elicit the NGF-TrkA signalling pathway in cholinergic neurons and retain full neurotrophic activity in the DRG assay","volume":"10","author":"Triaca","year":"2020","journal-title":"Biomolecules"},{"key":"B44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","article-title":"BDNF signaling in context: from synaptic regulation to psychiatric disorders","volume":"185","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/0888-7543(95)80226-c","article-title":"Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21\u2013q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy","volume":"26","author":"Weier","year":"1995","journal-title":"Genomics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0014-5793(95)01047-i","article-title":"Specific neurotrophin binding to leucine rich motif peptides of TrkA and TrkB","volume":"374","author":"Windisch","year":"","journal-title":"FEBS Lett."},{"key":"B47","doi-asserted-by":"publisher","first-page":"28133","DOI":"10.1074\/jbc.270.47.28133","article-title":"Nerve growth factor binding site on TrkA mapped to a single 24-amino acid leucine-rich motif","volume":"270","author":"Windisch","year":"","journal-title":"J. Biol. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1779769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:31:39Z","timestamp":1780291899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2026.1779769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":48,"alternative-id":["10.3389\/fbinf.2026.1779769"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2026.1779769","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1779769"}}